A Glimmer of Hope for Pancreatic Cancer

Recent advances in precision medicine and immunotherapy have transformed the once bleak outlook for many patients with solid tumors, including melanoma and non–small-cell lung cancer. Unfortunately, these newer approaches have not affected the dismal outcomes for patients with pancreatic adenocarcinoma. Only 8% of patients with this disease are cured, the lowest rate among any solid tumors.1 Within the next decade, pancreatic cancer is projected to become the second leading cause of death from cancer in the United States,2 which reflects the inadequacy of our current treatment options. Surgery is the only potential cure, but fewer than 20% of patients are . . .